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Enhanced Antigen-Specific Antitumor Immunity
with Altered Peptide Ligands
that Stabilize the MHC-Peptide-TCR Complex
tion of tumors of certain histologic types but silent in
most normal tissues in the adult (e.g., MAGE1-3); (3)
tissue-specific differentiation antigens specific to the
tissue type from which the tumor arose (e.g., gp100 and
tyrosinase). The latter two categories of tumor antigen
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low affinity of the peptide antigen for its presenting MHCJohns Hopkins University
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weak association of peptide with MHC molecules at
the surface of antigen-presenting cells resulting in poor
presentation of MHC-peptide ligand to T cells. SuchSummary
antigens are often characterized by an absence of fa-
vored residues at critical anchor positions involved inT cell responsiveness to an epitope is affected both
MHC binding. For weak tumor antigens that fall intoby its affinity for the presenting MHC molecule and
the low-affinity MHC binding category, replacement orthe affinity of the MHC-peptide complex for TCR. One
mutation of unfavorable anchor residues with more ef-limitation of cancer immunotherapy is that natural tu-
fective ones may greatly enhance MHC binding proper-mor antigens elicit relatively weak T cell responses,
ties (Lurquin et al., 1989; Gervois et al., 1996; Parkhurstin part because high-affinity T cells are rendered toler-
et al., 1996; Bakker et al., 1997; Dyall et al., 1998; Over-ant to these antigens. We report here that amino acid
wijk et al., 1998; Valmori et al., 1999). These alteredsubstitutions in a natural MHC class I–restricted tumor
peptides may more effectively activate T cell responsesantigen that increase the stability of the MHC-peptide-
against the wild-type peptide antigen by virtue of theTCR complex are significantly more potent as tumor
increased efficiency of presentation of the MHC-peptidevaccines. The improved immunity results from en-
complex to specific T cells. In both mouse and humanhanced in vivo expansion of T cells specific for the
studies, these anchor-modified peptides can elicit supe-natural tumor epitope. These results indicate peptides
rior T cell responses against the original antigen in vivothat stabilize the MHC-peptide-TCR complex may pro-
(Dyall et al., 1998; Rosenberg et al., 1998). Thus, en-vide superior antitumor immunity through enhanced
hanced stability of the MHC-peptide complex afforded
stimulation of specific T cells.
by the favorable anchor residue may result in a more
efficacious T cell response due to the presentation of
Introduction increased numbers of MHC-peptide ligands.
Some tumor antigens bind to their presenting MHC
A major endeavor in modern medicine is the enhance- with affinities in a similar range to strong viral antigens
ment of vaccine potency via manipulation of both the yet elicit weak endogenous immune responses (Lee et
antigen and the delivery system. Success in this effort al., 1999). For tumor antigens with high MHC affinities,
is critical in the development of effective cancer immu- the proposed mechanism for weak endogenous immune
notherapy. In particular, enhancement of T cell responses responses is that high-affinity T cells are actively toler-
to tumor antigens would lead to more potent treatments ized via anergy or deletion, thereby leaving a functional
(Pardoll, 2000). Endogenous T cell responses to both repertoire consisting of T cells bearing T cell receptors
murine and human cancers can be readily identified (TCR) with low affinity for MHC-peptide complexes. This
(reviewed in De Plaen et al., 1997; Robbins and Kawa- residual T cell repertoire is postulated to have escaped
kami, 1996). Tumor antigens recognized by T cells typi- active tolerance induction by virtue of its low affinity
cally fall into one of three categories (reviewed in Boon for MHC-peptide ligand. This mechanism is particularly
et al., 1997; Gilboa, 1999): (1) antigens whose peptide relevant for shared tumor antigens, which, because they
epitopes incorporate the product of a mutation specific are self-antigens, have had a long time period to induce
to the individual tumor (e.g., mutated oncogenes); (2) tolerance (Morgan et al., 1998).
nonmutated antigens expressed by a significant propor- The current study was designed to investigate the
effect of immunization with altered peptides in which
amino acids were substituted that affect the affinity of§ To whom correspondence should be addressed (e-mail: dmpardol@
the MHC-peptide complex for TCR rather than the affinityjhmi.edu).
k Present address: Genoway, 46 Alle´e d’Italie, 69007 Lyon, France. of peptide for MHC. We focused on a nonmutated H-2Ld-
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restricted peptide antigen derived from gp70 amino
acids 423–431, referred to as AH1 (SPSYVYHQF), which
is the dominant target for the CD8 T cell responses
against the CT26 colorectal tumor (Huang et al., 1996).
gp70 expression is silent in most normal tissues but
is active in many mouse tumors (Huang et al., 1996).
According to a computer algorithm developed to rank
order the half-time of disassociation of peptide to MHC,
AH1 is predicted to bind H-2Ld with higher affinity than
other peptides derived from gp70 (Parker et al., 1994).
AH1 features a proline in position two and an aliphatic
residue in position nine, consistent with the consensus
residues for H-2Ld binding peptides (Corr et al., 1992).
Here, we show that AH1 has relatively high affinity for
H-2Ld but provides relatively weak immunization against Figure 1. AH1 and pMCMV Peptides Bind H-2Ld with Similar Affinity
CT26 challenge. An amino acid substitution in AH1 that Either buffer alone or graded concentrations of the indicated peptide
does not alter MHC binding but rather increases the (pMCMV [YPHFMPTNL], p2Ca [LSPFSFDL], p91A-Tum V9 [QNHRAL
stability of the MHC-peptide-TCR complex by decreas- DLV]) were combined with 40 mM H-2Ld produced in mammalian
cells and exposed to immobilized pMCMV-C4 peptide on the bio-ing the off rate of TCR from MHC-peptide is significantly
sensor surface. The cysteine substitution at position 4 of pMCMVmore potent in activating T cells in vivo specific for the
facilitated immobilization of the peptide to the biosensor surfacenatural tumor epitope, resulting in enhanced systemic
and exhibits similar binding to H-2Ld as the native peptide. The
antitumor immunity. amount of H-2Ld bound to pMCMV-C4 is reflected by the change
in resonance units after 4 min.
Results
Tumor Antigen AH1 Binds MHC with High Affinity cate that AH1 is a high-affinity binding peptide of H-2Ld.
To analyze the role of MHC and TCR binding properties Thus, weak MHC binding does not account for the failure
on the immunogenicity of a tumor antigen, we chose of the AH1 peptide to serve as an effective immunogen.
the well-characterized mouse colorectal cancer, CT26.
AH1, an H-2Ld-restricted peptide, was identified as the
immunodominant antigen from CT26 recognized by Alanine Substitution of Residue Five in the AH1
Peptide Enhances Stability of theCD81 T cells in animals immunized with autologous
whole cell tumor vaccines (Huang et al., 1996). As with MHC-Peptide-TCR Complex
To determine the influence of TCR affinity for MHC-most natural tumor antigens derived from self-proteins,
AH1 peptide is a relatively weak immunogen when used peptide complex on immunogenicity, we studied TCR
binding to the natural H-2Ld-AH1 complex as well as toindependently from the tumor as a vaccine against CT26
even though it is a good target for activated antigen- a panel of alanine-substituted variant peptides. To over-
come the intrinsically low affinity of MHC-peptide forspecific CTL (Huang et al., 1996). To understand why the
peptide antigen does not immunize efficiently against TCR, we used the general approach of making multiva-
lent MHC and TCR complexes (Altman et al., 1996; O’Her-tumor formation and to determine if substitutions that
alter the stability of the trimeric complex might result in rin et al., 1997; Murali-Krishna et al., 1998). We generated
dimeric forms of TCR and MHC-peptide using an Ig scaf-stronger antitumor immunity, we first studied the physical
parameters of the interaction between H-2Ld and AH1 as fold to produce fusion proteins (Dal Porto et al., 1993;
O’Herrin et al., 1997; Greten et al., 1998). Binding waswell as the H-2Ld-AH1 complex and a cognate TCR.
To compare binding of the AH1 peptide to the MHC measured in both directions by flow cytometry by adding
peptide-loaded dimeric H-2Ld, Ld-Ig, to AH1-specific Tclass I molecule H-2Ld relative to other tumor antigens
and known H-2Ld binding peptides, we employed a pre- cells and dimeric TCR, CT-Ig, to peptide-loaded antigen-
presenting cells. The rank order of binding of eitherviously described assay using immobilized peptides and
surface plasmon resonance (Khilko et al., 1993; re- TCR to MHC-peptide on cells or MHC-peptide to TCR
expressing cells was essentially the same (Figure 2).viewed in Khilko et al., 1995). In this assay, the binding
of an “empty” soluble H-2Ld to an immobilized peptide Substitution of the consensus MHC anchor residue 2
(proline) resulted in reduced binding, although the inter-is competed for by graded concentrations of a test pep-
tide. The peptide pMCMV-C4 was immobilized, and the action was not totally abolished in either the TCR or
MHC binding assay. Other amino acids can be toleratedindicated competing peptides and H-2Ld were offered
in solution phase. AH1 bound H-2Ld as well as pMCMV in position 2 in the presence of strong C9 terminal anchor
residues as in p2Ca (LSPFSFDL) and Tum (QNHRALDL)and better than the other peptides tested as indicated
by the decreased change in resonance units, especially (Robinson and Lee, 1996). Peptides with substituted
residues 4, 6, 7, 8, and 9 resulted in background-levelat the lower peptide concentrations (Figure 1). pMCMV
has previously been shown to be a high-affinity H-2Ld binding similar to the negative control pMCMV. In con-
trast, peptides with substituted residues 1, 3, and 5 eachbinding peptide (Margulies et al., 1993). p2Ca and p91A-
Tum V9, another H-2Ld-restricted tumor antigen, are mediated more binding than wild-type AH1. Since AH1-A5
mediated the greatest binding of all the peptides tested,intermediate affinity MHC binding peptides (Alexander-
Miller et al., 1994; Corr et al., 1994). These results indi- we chose to fully characterize the binding of AH1-A5
Heteroclitic Tumor Antigen Stabilizes TCR Binding
531
tides to bind H-2Ld as described in Figure 1. Again,
the AH1 peptide competed for soluble H-2Ld as well as
pMCMV and nominally better than the other peptides
tested including AH1-A5 (Figure 3). Thus, the enhanced
binding mediated by the AH1-A5 peptide relative to the
AH1 peptide shown in Figure 2 is not a result of an
increased affinity for MHC.
H-2Ld-AH1-A5 Binds TCR with Higher Affinity
than H-2Ld-AH1
Surface plasmon resonance was used to directly mea-
sure the binding properties between TCR and the different
peptides complexed with H-2Ld. The CT26 TCR-Ig was
immobilized to the biosensor surface to measure the
binding characteristics of graded concentrations H-2Ld
complexed with AH1, AH1-A5, AH1-A7, and pMCMV.
Binding of MHC-peptide complexes to the immobilized
TCR was visualized as the time-dependent increase in
resonance units (Figure 4A). Based on steady-state bind-
ing levels, the equilibrium constants for dissociation, KD
for the interaction of the TCR-Ig protein to the soluble
H-2Ld complexes were determined (Figure 4B; Table 1).
H-2Ld-AH1-A5 resulted in more binding than H-2Ld-AH1
reflecting the stronger affinity (KD). Significant binding of
pMCMV-H-2Ld to the TCR was not detected as expected
demonstrating specificity. Independently, the kinetic dis-
sociation rate constants (koff) for each interaction were
determined using a direct fit algorithm (Table 1) with
the assumption of 1:1 Langmuir binding. Based on the
measured KD and koff, the kinetic association rate con-
stants, kon, were calculated. As shown in Table 1, the
on rates of the AH1 and AH1-A5 peptide complexes were
similar. However, the off rate of the AH1-A5 complex was
about 3-fold slower than the AH1 complex accounting
for the difference in affinity. The on rate of the H-2Ld-
AH1-A7 complex was about 4-fold slower than the H-2Ld-
AH1 complex, although the off rates were similar. Table 1
also summarizes the half-time of binding of the MHC-
peptide binding to the TCR based on the koff.
AH1-A5 Peptide Improved Cytolytic Activity
Mediated by an AH1-Specific T Cell CloneFigure 2. Binding of TCR to Ligand as Mediated by AH1 and AH1
As an initial step toward correlating TCR binding proper-with Alanine Substitutions
ties with immunogenicity, we analyzed the reactivity of theIn the left panel, the AH1-specific T cell clone was stained with
divalent H-2Ld, Ld-Ig, which had been loaded with the indicated AH1-specific T cell clone to the AH1 peptide as well as the
peptides, and analyzed by flow cytometry. In the right panel, T2-Ld panel of alanine-substituted variant peptides in chromium
cells were incubated in 10 mM of the indicated peptide, stained with release assays (Figure 5). 10 ng/ml (8.3 nM) AH1 peptide
a divalent single chain form of the TCR from the AH1-specific clone,
resulted in maximal specific lysis by the AH1-specificCT-Ig, and analyzed by flow cytometry. Both Ld-Ig and CT-Ig pro-
clone. When the anchor residues were changed to anteins were added in excess and visualized with IgG1-biotin and
alanine (AH1-A2 and AH1-A9), peptide-dependent sensi-Avidin-PE. Histograms of the relative cell number versus fluores-
cence are shown. The mean channel fluorescence is indicated in tization for lysis was abolished. Substitution at positions
each histogram. 4, 6, and 7 also resulted in background-level lysis similar
to the negative control pMCMV. Substitution in positions
1, 3, and 8 mediated approximately the same level of
for H-2Ld and H-2Ld-AH1-A5 for TCR compared with the lysis at AH1. However, the alanine substitution at posi-
wild-type AH1 peptide. tion 5 sensitized target cells for maximal lysis at z10-fold
lower concentration of peptide (1 ng/ml) and shifted the
entire dose response curve. With the exceptions of AH1-AH1 and AH1-A5 Peptides Bind MHC
with Similar Affinities A2 and AH1-A8, the cytolysis results correlated with
those obtained in the binding experiments (Figure 2).One possible mechanism to explain the increased binding
of TCR to MHC-peptide complexes containing AH1-A5 Thus, the increased affinity of the AH1-A5-mediated
MHC-TCR complex correlated with increased sensitiza-relative to the wild-type AH1 peptide is enhanced MHC
binding. We therefore compared the ability of the pep- tion of targets for cytolysis by the AH1-specific T cell clone.
Immunity
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Figure 3. AH1 and AH1-A5 Bind H-2Ld with
Similar Affinity
Either buffer alone or graded concentrations
of indicated peptide were combined with 40
mM H-2Ld and exposed to immobilized
pMCMV-C4 peptide on the biosensor sur-
face, as in Figure 1. The amount of H-2Ld
bound to pMCMV-C4 is reflected by the
change in resonance units on the Y axis after
1 min.
Vaccination Using AH1-A5 Peptide Improved In Vivo cell repertoire in vivo mimics that of the isolated CD81
T cell clone. Of relevance to cancer immunotherapy isT Cell Immunity to AH1 Peptide and CT26 Tumor
The enhanced apparent TCR affinity and stimulatory whether the increased binding between the cloned T
cell receptor and the H-2Ld-AH1-A5 complex as com-capacity of AH1-A5 for an individual T cell clone
prompted us to evaluate in vivo immunogenicity of AH1- pared to the H-2Ld-AH1 complex can result in a more
robust immune response in vivo against the AH1 epitopeA5 relative to the wild-type AH1 peptide. At issue is
whether a significant proportion of the AH1-specific T and ultimately the tumor, CT26. To determine if AH1-A5
Figure 4. AH1-A5 Has a Stronger Affinity and
a Longer Dissociation Time Than AH1
(A) Profiles from the biosensor of H-2Ld-pep-
tide binding to the TCR derived from the AH1-
specific clone are shown. Graded concentra-
tions (7.00, 2.33, 0.70, 0.233, and 0.07 mM) of
H-2Ld produced in bacteria complexed with the
indicated peptide were injected over 5300
resonance units of immobilized CT-Ig at a
flow rate of 5 ml/min. The change in resonance
units (RU) reflects binding of H-2Ld-peptide
to the surface over time. Data extrapolated
from these curves were used to determine the
dissociation rates (koff) using Biaevaluation
3.0 software and to the graph in Figure 4B.
Results of these analyses are shown in Table 1.
(B) Equilibrium binding constants (KD) were
derived from these curves using a nonlinear
1:1 Langmuir binding curve-fit on the Origin
program from Microcal 1.4 software (1, AH1-
A5; square, AH1; dotted line, AH1-A7; and
circle, pMCMV).
Heteroclitic Tumor Antigen Stabilizes TCR Binding
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Table 1. Affinity and Kinetic Constants for Binding of H-2Ld/Peptidea to T Cell Receptorb
Ld/Peptide koff (s21)c kon (s21M21)d KD (mM)e t1/2 (s)f
AH1 0.35 6 0.025 6.1 3 104 6 6.5 3 103 5.7 6 0.45 2.0 6 0.14
AH1-A5 0.11 6 0.017 5.8 3 104 6 1.0 3 104 1.9 6 0.18 6.3 6 0.97
AH1-A7 0.28 6 0.023 1.6 3 104 6 6.4 3 103 18 6 7.3 2.4 6 0.20
pMCMVg ,,60 6 50
a H-2Ld protein was produced in E. coli and folded separately around each peptide.
b The single-chain CT26 T cell receptor was produced in plasmacytoma cells and immobilized to a CM5 chip with amine coupling.
c The koff values were determined using the BIAevaluation 3.0 program for 1:1 Langmuir dissociation kinetics.
d The kon values were calculated from koff and KD.
e The KD values were obtained from equilibrium binding data.
f T1/2 equals ln 2 divided by koff.
g H-2Ld/pMCMV interaction with CT26 T cell receptor was too weak to permit accurate assessment of binding parameters.
is a stronger tumor antigen than endogenous AH1, we CD81 H-2Ld-AH1-specific T cells as assessed by stain-
ing with Ld-Ig loaded with AH1 (Figure 6C). Vaccinationcompared these two peptides in a vaccination study.
For this study, we used dendritic cells as antigen- with AH1-A5 loaded dendritic cells resulted in a 5- to
10-fold greater expansion of AH1-specific T cells relativepresenting cells (Mayordomo et al., 1995) derived from
the spleen and loaded overnight with peptide in serum- to the AH1-loaded dendritic cell vaccine. Although quali-
tative differences of the T cell populations after vaccina-free medium. The phenotype of these cells is similar to
that of dendritic cells described by others (reviewed tion with different dendritic cells are not measured here,
these results show a significant quantitative differencein Banchereau and Steinman, 1998); they express high
levels of MHC class II, costimulatory molecules (B7.1 in the T cell populations.
Using the same vaccination protocol, we evaluatedand B7.2), and CD11c (Figure 6A). By staining the cells
with the dimeric TCR, CT-Ig, as described in Figure 2, whether the increased in vivo stimulation of AH1-spe-
cific T cells by the AH1-A5 peptide resulted in enhancedwe determined the most efficient conditions for peptide
loading. Then, using the same method, we determined antitumor immunity (Figure 6D). Development of tumors
in mice treated with unpulsed dendritic cells, dendriticthat the dendritic cells were loaded with similar amounts
of AH1 and AH1-A5 peptides. cells pulsed with pMCMV, or AH1-A7 occurred at the
same rate as in untreated mice. Vaccination with AH1-To determine the relative effect of these peptide-
loaded dendritic cells on the tumor-specific T cell re- loaded dendritic cells induced a significant delay in tu-
mor growth relative to untreated mice (p 5 0.001). Tu-sponse, we primed and boosted mice with dendritic
cells before removing the spleen. After a single in vitro mor-free survival was also significantly increased with
the treatment of AH1-A5-pulsed dendritic cells relativestimulation, we analyzed the cells for both CT26-specific
lysis and binding to the Ld-Ig loaded with AH1. Vaccina- to AH1-pulsed dendritic cells (p 5 0.025). Thus, selection
of a peptide variant that stabilized the trimolecular com-tion with AH1-A5 peptide resulted in significantly greater
lysis of CT26 targets (Figure 6B). This increased activity plex by decreasing TCR off rate resulted in enhanced
in vivo activation and expansion of antigen-specific Twas associated with an increase in the percentage of
cells and superior antitumor immunity.
Discussion
A structural understanding of the formation of a ternary
MHC-peptide-TCR complex suggests that particular
amino acid residues of the bound peptide contribute
predominantly either to MHC interactions (anchor or agre-
topic residues) or to TCR interactions (epitopic or anti-
genic residues). This compartmentalized view of peptide
interactions with MHC and TCR is most likely incorrect
in detail but nevertheless offers a simplified framework
of conceptualizing the effects of single residue amino
acid substitutions of antigenic peptides. With the initial
demonstrations that amino acid alterations in T cell epi-
topes could enhance stimulation of T cell populations spe-
cific for the original epitope, epitope modification has be-
come an attractive approach to augment antigen-specific
Figure 5. AH1-A5 Mediates More Cytolytic Activity Than the Wild-
immunotherapies (Solinger et al., 1979; Boehncke et al.,Type Tumor Antigen, AH1
1993; Chen, 1999). Indeed, amino acid substitutions that51Cr-labeled MC57G-Ld cells (3 3 103) were combined with the AH1-
enhance binding affinity of peptide for the presentingspecific T cell clone (1.5 3 104) and graded concentrations of peptide
MHC molecule have been demonstrated to improve theas indicated on the X axis. Percent lysis was calculated after 4 hr
at 378. immunogenicity of a number of MHC class I–restricted
Immunity
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Figure 6. Immunization with AH1-A5-Loaded
Dendritic Cells Results in Enhanced Lytic Ac-
tivity, Frequency of CD81 CT26-Specific T
Cells, and Tumor-Free Survival Relative to Im-
munization with AH1-Loaded Dendritic Cells
(A) Characteristics of cell surface markers
and peptide loading of dendritic cells derived
from the spleen are shown. Dendritic cell
populations from the spleen were enriched
to 60%–80% with a BSA gradient and adher-
ence to plastic. After a 12 hr incubation with
100 or 300 mg/ml peptide, the cells were ana-
lyzed for cell surface markers. Expression of
MHC class II, CD11c, and B7-2 were examined.
In the first row, the thick line represents stain-
ing with the indicated antibody, and the thin
line represents background fluorescence from
an isotype-matched control antibody. In the
second row, dendritic cells are stained with
CT-Ig. In the left panel, the thick line repre-
sents cells incubated with 300 mg/ml AH1
peptide, the thin line represents cells incu-
bated with 100 mg/ml AH1 peptide, and the
dotted line represents cells incubated with-
out peptide. In the right panel, the thick line
represents cells incubated with 300 mg/ml
AH1 peptide, the thin line represents cells
incubated with 300 mg/ml AH1-A5 peptide,
and the dotted line represents cells incubated
without peptide.
(B–D) BALB/c mice were injected on day –14
and day –7 subcutaneously in both hind
flanks with 1 3 105 dendritic cells pulsed with
300 mg/ml of the indicated peptides. (B) Lytic
activity specific for CT26 targets from mice
immunized with peptide-pulsed dendritic cells.
CTL derived from mice were examined 5 days
after in vitro stimulation with CT26 expressing
B7. Background lytic activity from spleen cells
of a naive mouse treated in parallel was sub-
tracted. A representative experiment of two
mice per group is shown. (C) Frequency of
AH1-specific T cells was measured 7 days
after in vitro stimulation. The peptide used to
pulse the dendritic cells is indicated on top. The numbers in the right-hand corner indicate the percent antigen-specific CD81 cells measured.
(D) On day 0, 5 3 104 CT26 tumor cells were injected subcutaneously in the left hind flank and tumor-free survival was monitored for 38 days.
N represents the number of mice in each group pooled from two independent experiments performed under identical conditions. The survival
differences analyzed on a Kaplan-Meier curve with Mantel-Cox statistics indicates that the difference between treatment with DC pulsed with
no peptide verses DC pulsed with AH1 (p 5 0.001) and DC pulsed with AH1 verses DC pulsed with A5 (p 5 0.025) are significant.
tumor antigens (Gervois et al., 1996; Parkhurst et al., that correlates with increased TCR interactions (Zhang
et al., 1992; Balendiran et al., 1997). However, using an1996; Bakker et al., 1997; Dyall et al., 1998; Overwijk et
al., 1998; Valmori et al., 1999). Here, we have demon- H-2Ld crystal structure to predict the orientation of the
fifth residue of the QL9 peptide (phenylalanine) suggestsstrated that an amino acid substitution that enhances
the affinity of the MHC-peptide complex for the TCR that it is buried in pocket C of H-2Ld (Speir et al., 1998).
The crystal structure of p29 peptide complexed withalso enhances expansion and activation of polyclonal
T cell responses specific for the wild-type antigen. In H-2Ld shows the asparagine at P5 is pointing toward
the a1 helix of the MHC (Balendiran et al., 1997). Pocketthe case of the immunodominant AH1 tumor antigen
studied here, this enhanced in vivo immunization results C of the mid-cleft region of H-2Ld is shallow, hydropho-
bic, and does not require binding of a consensus residuein superior immunity against challenge with the CT26
tumor. (Balendiran et al., 1997). Given these disparities in orien-
tation of P5 for different H-2Ld binding peptides, oneSubstitution of alanine for valine at position five (P5)
of the AH1 peptide does not significantly change peptide cannot accurately predict the orientation of P5 in the
AH1 peptide. It is thus unclear whether the altered TCRbinding to MHC but increases the affinity of MHC-pep-
tide for TCR, suggesting that it is epitopic. Consistent affinity afforded by the valine to alanine substitution of
AH1 is due to direct contact of P5 with the TCR or ratherwith our interpretations, analysis of H-2Ld binding to the
tum peptide suggests that arginine at P5 also binds through affects on the relative orientation of the adjacent
tyrosines.the TCR (Robinson and Lee, 1996). Amino acids at this
position are predicted to have high solvent accessibility Since the AH1-A5 peptide was originally identified
Heteroclitic Tumor Antigen Stabilizes TCR Binding
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using only a single AH1-specific T cell clone in vitro, pressing b-galactosidase efficiently protects animals
the heteroclitic properties were somewhat unexpected. against challenge with CT26-expressing b-galactosi-
Differences in in vitro reactivity using a single T cell clone dase (Bronte et al., 1995).
might not necessarily predict the relative reactivities The measured affinity of the H-2Ld-AH1 complex for the
between wild-type AH1 and AH1-A5 among the diverse cognate TCR was at the low end of the range of reported
in vivo polyclonal T cell response. The finding that AH1- affinities for other agonist MHC class I–restricted antigen
A5 was so much more efficient at expanding and activat- TCR pairs (reviewed in Davis et al., 1998). However,
ing T cells specific for wild-type AH1 suggests that a given the variabilities in construction of soluble TCRs
large T cell repertoire exists in vivo whose TCR displays and MHCs used in the different studies as well as varia-
common structural features and reactivity patterns to tions affecting surface plasmon resonance measure-
the original T cell clone. ments, it is difficult to make reliable comparisons among
As with many other antigens, certain Vb segments different studies. The roughly 3-fold enhanced TCR af-
dominate the AH1-specific T cell response. We found a finity of H-2Ld-AH1-A5 relative to H-2Ld-AH1 is reflected
predominance of Vb8.3, the Vb segment expressed by in a 3-fold decreased kd; the ka for H-2Ld-AH1 and H-2Ld-
the T cell clone, within polyclonal AH1-specific T cell AH1-A5 is essentially identical. This 3-fold difference in
lines. Colombo and colleagues have identified T cell affinity and off rate results in a roughly 10-fold enhance-
populations specific to AH1 expressing other Vb regions ment in activation of the AH1 T cell clone. The elements
(personal communication). We are currently determining of MHC-peptide binding to TCR that are most relevant
if there are qualitative differences in the repertoire of to T cell stimulation are still not yet completely resolved.
AH1-specific T cells activated by in vivo immunization While some groups have presented data favoring a
with AH1-A5 versus wild-type AH1. It is possible that strong correlation between off rate and stimulatory ca-
the AH1-reactive T cell repertoire specifically expanded pacity (Chen et al., 1994; Savage et al., 1999), others have
by AH1-A5 represents a subset of the total AH1-reactive argued for an important contribution of on rate and/or
repertoire. Whether or not this is the case, the enhanced overall affinity in determining functional T cell reactivity
TCR binding properties of AH1-A5 relative to wild-type (Alam et al., 1996). For other cases, a clear cut correla-
AH1 clearly provides enough of an advantage at the tion is lacking and other characteristics may be involved
population level in vivo to result in a net enhancement (Al-Ramadi et al., 1995; reviewed in Manning and Kranz,
in activation and expansion of AH1-specific T cells. 1999). Of note, the measured off rates of H-2Ld-AH1-A7
The overall antitumor immune response afforded by and H-2Ld-AH1 for TCR are similar though AH1-A7 fails
various immunotherapies is a combination of multiple to stimulate the AH1-specific T cell clone. This result
types of responses to multiple tumor antigens not limited further suggests that off rate of MHC-peptide from TCR
to, for example, a single antigen. The finding that modifi- is not the sole determinant of biological activity.
cation of a single epitope can significantly affect antitu- While the TCR affinity of H-2Ld-AH1 and its biological
mor immunity raises the possibility that additive effects activity in stimulating the AH1 clone are consistent with
of multiple antigenic modifications in a polyvalent vac- AH1 being a weak agonist, it is possible that AH1 has
cine may provide more potent protection. While substi- partial antagonist properties as well. Indeed, it has been
tution of MHC binding anchor residues is a reasonable suggested that low TCR affinities for tumor antigens
approach to modify epitopes displaying low MHC affini- could lead to tolerance in tumor-specific T cells. A recent
ties, it is likely that the poor immunogenicity of most study in melanoma patients identified an unresponsive
tumor antigens is due instead to tolerization of high- or “anergic” phenotype among populations of tyrosinase-
affinity T cells, thereby leaving an available repertoire specific T cells from draining lymph nodes containing
of low-affinity T cells. The feasibility of activating these melanoma metastases (Lee et al., 1999). If tolerance is
remaining low-affinity populations of T cells was demon- being induced, amino acid substitutions in tumor anti-
strated in studies using HA as a model self- and tumor
gens that result in increased TCR affinity may enhance
antigen (Morgan et al., 1998).
immunogenicity by converting peptides from partial an-
The gp70 antigen from which the AH1 epitope is de-
tagonists to full agonists for populations of specific Trived represents a prototype example of a shared tumor
cells in vivo. Further functional analysis of the popula-antigen whose expression has been selectively upregu-
tions of AH1-specific T cells activated in vivo by wild-lated in CT26 and in many other mouse tumors (Jaffee
type AH1 versus AH1-A5 may shed light on how peptideand Pardoll, 1996). Although gp70 expression was not
substitutions effecting the stability of the MHC-peptide-detected in the thymus in our previous study (Huang et
TCR complex affect the balance between activation andal., 1996), it is quite possible that natural expression of
tolerance of tumor-specific T cells.gp70 tolerizes high-affinity T cells. Evidence for such a
mechanism has indeed been observed with other en-
dogenous retroviral gene products such as the MMTV- Experimental Procedures
derived superantigens (Marrack et al., 1993). Consistent
with this idea, AH1 peptide is a weak immunogen despite Peptides
All peptides were purified to greater than 95% purity and purchasedthe fact that it is the dominant target for CT26-specific
from Macromolecular Resources (CO), Chiron (CA), or PrincetonCTL responses. For example, immunization with recom-
BioMolecules (OH). The sequences of the peptides are SPSYVYHQFbinant vaccinia expressing either full-length gp70 or an
(AH1), APSYVYHQF (AH1-A1), SASYVYHQF (AH1-A2), SPAYVYHQF
AH1 minigene downstream of an endoplasmic reticulum (AH1-A3), SPSAVYHQF (AH1-A4), SPSYAYHQF (AH1-A5), SPSY
signal sequence fails to protect animals against CT26 VAHQF (AH1-A6), SPSYVYAQF (AH1-A7), SPSYVYHAF (AH1-A8),
challenge (K. Gorski, E. M. J., and D. M. P., unpublished SPSYVYHQA (AH1-A9), YPHFMPTNL (pMCMV), and YPHCMPTNL
(pMCMV-C4), LSPFSFDL (p2Ca), and QNHRALDLV (p91A-Tum V9).data). In contrast, immunization with vaccinia virus ex-
Immunity
536
Biosensor Analysis CT-Ig was generated similarly to Ld-Ig and to other divalent TCRs
constructed (Plaksin et al., 1997; Lebowitz et al., 1998). In place ofThe real-time surface plasmon resonance experiments utilized the
Biacore 2000. All immobilization and binding experiments were per- the MHC fragment in Ld-Ig, a fragment encoding a single chain TCR
from the AH1-specific T cell clone was inserted. The variable domainformed at 258C at a flow rate of 5 ml/minute. The binding buffer,
HBST (10 mM Hepes [pH 7.5], 3.4 mM EDTA, 15 mM sodium chloride, of the b chain of the T cell clone was identified by recognition of
the vb8.3 antibody (1B3.3). The variable region family of the a chainand 0.005% Tween 20), was used to dilute the solution phase ligand.
The cell culture–produced H-2Ld used in the peptide binding experi- of the T cell clone was identified by PCR (as determined by David
Woodland). The family member was identified as va4.11 by sequenc-ments have been described (Boyd et al., 1992; Goldstein et al., 1997).
40 mM H-2Ld was used in each reaction. The change in binding ing. The a and b chains were amplified from cDNA from the AH1-
specific clone using these primers: 59va4.11.AseI GGAATTCATT(resonance units) was determined 1 min after addition to the peptide
surface. Sulfo-SMCC (sulfosuccinimidyl 4-(N-maleimidomethyl)cyclo- AATGACTCAGTAACCCAGATGCAA, 39vaHindIII ATAAGAAAGCTT
TCCTGGTTTTACTGATAATTT, 59b8.3NdeI ATAAGAATGCGGCCGhexane-1-carboxylate) (Pierce) was used to couple between 100 and
200 resonance units of peptides through a cysteine to the dextran- CCGAGGTCGCAGTCACCCAAAGCCCTA, and 39cbXhoI CCGCCTC
GAGTCAGTCTGCTCGGCCCCAGGCCTCTGC. The fragments werecoated CM5 sensor chip as previously reviewed and described (Mar-
gulies et al., 1996). After binding the MHC to the peptide surface, inserted into pCR2.1 (Invitrogen) to verify the sequence. The NotI-
XhoI fragment harboring the coding region of v-d-j-c of the b chainthe surface was regenerated with 50 mM phosphoric acid. Approxi-
mately 5000 resonance units of the single chain TCR in 25 mM was inserted into the same sites of pET-scTCR to replace the exist-
ing b chain (Plaksin et al., 1997). The AseI-HindIII fragment encodingsodium acetate (pH 5.1) was coupled to the CM5 chip with amine
chemistry (NHS/EDC) as determined by the BIAevaluation 3.0 Appli- the v-j region of the a chain was then inserted NdeI-HindIII of pET-
scTCR leaving the linker between the a and the b chain (Chung etcation Wizard. A blank surface was prepared using the same method
without protein. The TCR surface was cleared of MHC-peptide bind- al., 1994) and the rest of the vector, pET211 (Novagen) intact. The
single chain TCR was amplified with primers 59MluITCR GATCACGing with a 5 min wash with HBST. The fit of curves with a standard
error of less than 5% of the calculated koff and residuals less than CGTCGATGGACTCAGTAACCCAGA and 39SalITCR GATCGTCGA
CGTCTGCTCGGCCCCAGGCCTC. The resulting fragment was in-2 were considered.
To obtain equilibrium constants, the data were nonlinearly fit to serted into pCR2.1 for sequencing and then the MluI-SalI fragment
was inserted into the MluI and XhoI sites of pX-Ig. As with Ld-Ig,the following equation using the Origin program from Microcal soft-
ware: R 5 (Rmaxc)-(KD1c) where R 5 resonance units, Rmax 5 maxi- this plasmid was electroporated into J558L cells, and a clone that
reacted with antibodies to the cb region (H57-597, PharMingen),mum resonance units as determined by the nonlinear fit, c 5 concen-
tration of analyte, and KD 5 the affinity constant. vb8 (F23.1, PharMingen), and IgG1 (Caltag) (data not shown), was
expanded to produce protein for staining antigen presenting cells
and binding experiments.Cells
CT26, CT26-B7 that express human B7.1, and MC57G-Ld were cul-
tured in complete medium (RPMI-1640 supplemented with 10% fetal Antibodies, Cell Staining, and Flow Cytometric Analysis
To examine peptide-mediated binding, 2 3 105 CT26 T cell clone wascalf serum, 100 units/ml penicillin, 100 units/ml streptomycin, 13
MEM nonessential amino acids [Sigma], 1 mM sodium pyruvate, 10 incubated on ice with z1 mg Ld-Ig loaded with different peptides for
1–2 hr in flow cytometry wash buffer (13HBSS (Gibco), 2% fetal calfmM Hepes [pH 7.5], 2 mM L-glutamine, and 0.1 mM b-mercaptoetha-
nol) as described (Griswold and Corbett, 1975; Huang et al., 1996). serum, 10 mM Hepes [pH 7.5], and 0.1% sodium azide). The Ld-Ig-
peptide was visualized with IgG1-biotin (PharMingen) and avidin-PET2-Ld cells were cultured in the same medium (O’Herrin et al., 1997).
The AH1-specific T cell clone was generated from limiting dilution (Caltag) on a Becton-Dickinson FACScan flow cytometer. When visual-
izing antigen-specific T cells after an in vitro stimulation, CD4-FITCof a CT26 CTL line that was isolated from a spleen of a BALB/c
mouse vaccinated with CT26 transduced with GM-CSF (Huang et (RM2501-3, Caltag), B220-FITC (PharMingen), and CD8-cychrome
(PharMingen) were also included with the avidin-PE to facilitateal., 1996). The T cell clones were stimulated in vitro every 7 days
as described (Huang et al., 1996). Splenocytes were stimulated in detection of the CD81 cells.
For visualization of peptide-loaded H-2Ld complexes, T2-Ld cellsvitro by the same method. In brief, the spleens were crushed and
red blood cells were lysed (Kruisbeek, 1993). After two washes in were incubated overnight at 258C. T2-Ld cells were then incubated
with 10 mM peptide for 2 hr at 378C. Approximately 1 mg CT-Ig wascomplete medium, the 4 3 106 cells were combined with 1 3 105
mitomycin C-treated CT26-B7 and 10 units/ml IL-2 in 2 ml complete added to either 3 3 105 T2-Ld cells or peptide-pulsed dendritic cells,
the cells were incubated on ice for 1–2 hr, and, then visualized bymedium in 24-well plates.
Dendritic cells were generated from the spleen as described (Inaba flow cytometry as described with Ld-Ig. The antibody 14-4-4, which
recognizes MHC class II (American Type Cell Collection), anti-CD80,et al., 1998). The dendritic cells were loaded overnight in 100 or 300
mg/ml peptide in serum-free AIMV medium supplemented with 0.1 mM which recognizes B7.1 (PharMingen), and CD11c (PharMingen) were
used in analyzing the cell surface marker of the dendritic cells.b-mercaptoethanol, 100 units/ml penicillin, and 100 units/ml strepto-
mycin. Excess peptide was removed in three washes of Hanks buffer
(Gibco). Chromium Release Assays
One million target cells were labeled in 100 ml complete medium
and 200 mCi 51Cr at 378C for 1–1.5 hr. Target cells were washed threeConstruction, Expression, and Purification of Ld-Ig and CT-Ig
Ld-Ig, the divalent H-2Ld protein was constructed, expressed, and times to remove excess chromium. To determine which peptides
mediate lysis of the AH1-specific clone, 51Cr-labeled MC57G-Ldpurified using described methods (Schneck et al., 1999). In brief,
the BALB/c H-2Ld cDNA from pLd.444 (Huang et al., 1996) was cells (3 3 103) and AH1-specific T cell clone (1.5 3 104) were added
to 10-fold serial dilutions of the indicated peptides in a total of 200 mlamplified using primers 59LdMluI ATACGCGTCGCAGATGGGGGC
GATGGCTCC and 39LdXhoI ACCTCGAGTGCGGCCGCCCATCTC in a round-bottom 96-well plate for 4 hr at 378C. Half of the superna-
tent was removed and the gamma irradiation was counted. To deter-AGGGTGAGGGG. The fragment was digested with MluI and XhoI
and inserted into the same sites of pX-Ig (Dal Porto et al., 1993). mine the tumor specific lysis from splenocytes after vaccination, 3 3
103 51Cr-labeled CT26 cells were added to varying concentrationsThe sequence was verified. The resulting plasmid was cotransfected
by electroporation with a human b2-microglobulin expression plas- of splenocytes that had been stimulated in vitro for 5 days at a
40:1 ratio with mitomycin C-treated CT26-B7. Each data point wasmid into J558L plasmacytoma cells. A clone that secreted relatively
high levels of protein, as determined by ELISAs specific for H-2Ld performed in triplicate and then averaged. The shown experiments
are a representative of an example of at least two experimentsor the IgG1 portion of the molecule, was grown in Hybridoma-SFM
(Gibco), and protein was purified from supernatants by affinity chro- performed with each peptide. Data are expressed as % specific
lysis 5 (measured release 2 spontaneous release) 2 (maximummatography to the variable region of the Ig portion. Purified Ld-Ig
was loaded with peptide by incubating it with z200-fold excess release 2 spontaneous release) 3 100. Activity of splenocytes from
naive mice was subtracted from activity of splenocytes from vacci-peptide for 1–5 days. The resulting protein was used to stain antigen-
specific T cells. nated mice.
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Protein Expression and Purification ing of an antigenic peptide to a major histocompatibility complex
class I molecule and the role of b2-microglobulin. Proc. Natl. Acad.H-2Ld (Balendiran et al., 1997) and b2-microglobulin (Shields et al.,
1998) were produced in bacteria similarly to a described procedure Sci. USA 89, 2242–2246.
(Kurucz et al., 1993; Li et al., 1998). The H-2Ld preparations were made Bronte, V., Tsung, K., Rao, J.B., Chen, P.W., Wang, M., Rosenberg,
in parallel; each of the indicated peptides were folded with H-2Ld S.A., and Restifo, N.P. (1995). IL-2 enhances the function of recombi-
and b2-microglobulin separately. The H-2Ld-b2-microglobulin-peptide nant poxvirus-based vaccines in the treatment of established pul-
complexes were purified from aggregates on a Sephadex 75 gel monary metastases. J. Immunol. 154, 5282–5292.
filtration column, dialyzed against HBST, and quantitated using the
Chen, L. (1999). Mimotopes of cytolytic T lymphocytes in cancerUV-1601 Shimadzu spectrophotometer before using in binding ex-
immunotherapy. Curr. Opin. Immunol. 11, 219–222.periments.
Chen, W., Khilko, S., Fecondo, J., Margulies, D.H., and McCluskey,
J. (1994). Determinant selection of major histocompatibility complexMice and Immunizations
class I-peptide affinity and is strongly influenced by nondominantSix- to eight-week-old female BALB-CanNCr mice were purchased
anchor residues. J. Exp. Med. 180, 1471–1483.from the National Cancer Institute. Mice were injected with 1 3 105
dendritic cells in the left- and right-hind flank subcutanously on days Chung, S., Wucherpfennig, K.W., Friedman, S.M., Hafler, D.A., and
–14 and –7. On day 0, mice were injected subcutanously in the left Strominger, J.L. (1994). Functional three-domain single-chain T-cell
flank with 5 3 104 CT26 cells. Tumor-free survival was assessed by receptor. Proc. Natl. Acad. Sci. USA 91, 12654–12658.
detection of a palpable solid tumor at the site of injection. At 6 days,
Corr, M., Boyd, L.F., Frankel, S.R., Kozlowski, S., Padlan, E.A., andwe began to monitor for palpable tumors. Tumors developed in
Margulies, D.H. (1992). Endogenous peptides of a soluble majormost of the untreated mice within 2 weeks. The statistics were
histocompatibility complex class I molecule, H-2Lds: sequence motif,analyzed using the software StatView 5.0.1 (SAS Institute).
quantitative binding, and molecular modeling of the complex. J.
Exp. Med. 176, 1681–1692.
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